HRP20020537A2 - Ep4 receptor selective agonists in the treatment of osteoporosis - Google Patents

Ep4 receptor selective agonists in the treatment of osteoporosis Download PDF

Info

Publication number
HRP20020537A2
HRP20020537A2 HRP20020537A HRP20020537A2 HR P20020537 A2 HRP20020537 A2 HR P20020537A2 HR P20020537 A HRP20020537 A HR P20020537A HR P20020537 A2 HRP20020537 A2 HR P20020537A2
Authority
HR
Croatia
Prior art keywords
phenyl
pyrrolidin
butyl
hydroxy
oxo
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Kimberly O'keefe Cameron
Huazhu Ke
Bruce Allen Lefker
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HRP20020537A2 publication Critical patent/HRP20020537A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20020537 1999-12-22 2002-06-20 Ep4 receptor selective agonists in the treatment of osteoporosis HRP20020537A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17135399P 1999-12-22 1999-12-22
PCT/IB2000/001711 WO2001046140A1 (en) 1999-12-22 2000-11-20 Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (1)

Publication Number Publication Date
HRP20020537A2 true HRP20020537A2 (en) 2004-12-31

Family

ID=22623430

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20020537 HRP20020537A2 (en) 1999-12-22 2002-06-20 Ep4 receptor selective agonists in the treatment of osteoporosis

Country Status (36)

Country Link
US (2) US6737437B2 (xx)
EP (1) EP1110949B1 (xx)
JP (1) JP2001181210A (xx)
KR (1) KR100419681B1 (xx)
CN (1) CN1413190A (xx)
AP (2) AP2001002357A0 (xx)
AT (1) ATE250575T1 (xx)
AU (2) AU1293101A (xx)
BG (1) BG106882A (xx)
BR (1) BR0016560A (xx)
CA (1) CA2329678A1 (xx)
CO (1) CO5251453A1 (xx)
CR (1) CR6678A (xx)
CZ (1) CZ20022048A3 (xx)
DE (1) DE60005471T2 (xx)
DK (1) DK1110949T3 (xx)
EA (1) EA005293B1 (xx)
EE (1) EE200200355A (xx)
ES (1) ES2204458T3 (xx)
GE (1) GEP20043203B (xx)
HR (1) HRP20020537A2 (xx)
HU (1) HUP0005001A3 (xx)
IL (1) IL140325A0 (xx)
IS (1) IS6388A (xx)
MA (1) MA26852A1 (xx)
MX (1) MXPA02006322A (xx)
NO (1) NO20022925D0 (xx)
OA (1) OA12117A (xx)
PE (1) PE20010953A1 (xx)
PL (1) PL356662A1 (xx)
PT (1) PT1110949E (xx)
SK (1) SK8552002A3 (xx)
TR (2) TR200201643T2 (xx)
UA (1) UA72293C2 (xx)
WO (1) WO2001046140A1 (xx)
ZA (1) ZA200007694B (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
PT1339678E (pt) 2000-11-27 2007-11-30 Pfizer Prod Inc Agonistas selectivos do receptor ep4 no tratamento de osteoporose
BR0211201A (pt) * 2001-07-16 2004-07-13 Hoffmann La Roche Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
AU2002328338C1 (en) 2001-07-16 2009-01-08 Ono Pharmaceutical Co., Ltd 2 pyrrolidone derivatives as prostanoid agonists
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
TWI313608B (en) * 2001-07-23 2009-08-21 Ono Pharmaceutical Co Lower bone mass treating agent containing er4 agonist as active ingredient
CA2467061A1 (en) * 2001-11-12 2003-05-22 Ono Pharmaceutical Co., Ltd. Sustained release film preparation for local administration comprising prostaglandin derivative as active ingredient
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
JP2005519879A (ja) * 2001-12-03 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド Ｅｐ４受容体作動剤とその組成物および方法
EP1458679B1 (en) * 2001-12-20 2010-01-20 Merck Serono SA Pyrrolidine derivatives as prostaglandin modulators
JP4547912B2 (ja) * 2002-03-05 2010-09-22 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
CA2479222A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
CA2488001C (en) 2002-06-06 2011-03-22 Merck Frosst Canada & Co. 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
JP4754820B2 (ja) 2002-06-10 2011-08-24 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγラクタムおよびその使用
TW200413000A (en) 2002-10-10 2004-08-01 Ono Pharmaceutical Co Intrinsic repair factor producing accelerator
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2004043354A2 (en) 2002-11-08 2004-05-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
MXPA05007341A (es) * 2003-01-10 2005-09-30 Hoffmann La Roche Derivados de 2-piperidona como agonistas de prostaglandina.
US7256211B1 (en) 2003-01-21 2007-08-14 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medical use thereof
US7276531B2 (en) 2003-03-03 2007-10-02 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US6734206B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US7179820B2 (en) 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
WO2005012232A2 (en) * 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
NZ545401A (en) 2003-09-04 2008-10-31 Merck & Co Inc Ophthalmic compositions for treating ocular hypertension
US7494983B2 (en) 2003-09-04 2009-02-24 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
WO2006020003A2 (en) 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2006061366A1 (en) 2004-12-06 2006-06-15 Laboratoires Serono S.A. Pyrrolidin-2-one derivatives for use as dp1 receptor agonists
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
WO2006118173A1 (ja) 2005-04-28 2006-11-09 Ono Pharmaceutical Co., Ltd. 経皮吸収製剤
KR100686186B1 (ko) * 2005-06-13 2007-02-26 영진종합건설 주식회사 교량용 배수 구조물
AU2006277786B2 (en) 2005-08-09 2012-09-06 Asterand Uk Acquisition Limited EP2 receptor agonists
KR20090075864A (ko) 2006-10-26 2009-07-09 오노 야꾸힝 고교 가부시키가이샤 첨부제
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
US8063240B2 (en) 2007-11-14 2011-11-22 Cayman Chemical Company, Incorporated Prostaglandin E1 and E2 analogs for the treatment of various medical conditions
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
JP6052175B2 (ja) 2011-08-02 2016-12-27 小野薬品工業株式会社 左室拡張機能改善剤
CN106748951B (zh) 2012-07-19 2020-07-24 开曼化学股份有限公司 作为在治疗ep4介导的疾病和病状中使用的ep4受体选择性激动剂的二氟内酰胺化合物
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
SG11201507470WA (en) 2013-03-15 2015-10-29 Cayman Chemical Co Inc Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
AU2014290512A1 (en) 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US10400000B2 (en) 2015-06-12 2019-09-03 Simon Fraser University Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR897566A (fr) 1942-08-28 1945-03-26 Bopp & Reuther Gmbh Machine à rotors
US3528961A (en) 1966-08-16 1970-09-15 Allied Chem Monoazo dyes from e-caprolactam
US3780095A (en) 1970-04-08 1973-12-18 Byk Gulden Lomberg Chem Fab Acylated anilino-carboxylic acids and their salts
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
SE7414770L (xx) 1973-12-13 1975-06-16 Merck & Co Inc
DK366475A (da) 1974-08-30 1976-03-01 Merck & Co Inc Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4055596A (en) 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) * 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4243678A (en) 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de) 1980-11-11 1982-06-24 A. Nattermann & Cie GmbH, 5000 Köln N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0068968B1 (fr) 1981-06-16 1985-09-18 Choay S.A. Nouveaux médicaments contenant à titre de substance active des composés du type arylbenzènesulfonamide et leurs procédés de préparation
AU6427596A (en) * 1992-04-14 1996-10-31 Alfred Maximillian Stessl A boat hull
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US6426359B1 (en) * 1996-12-20 2002-07-30 Pfizer Inc. Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
JP2002527400A (ja) * 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨形成刺激方法
WO2000021532A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption

Also Published As

Publication number Publication date
DE60005471D1 (de) 2003-10-30
BR0016560A (pt) 2002-09-10
BG106882A (en) 2003-02-28
IS6388A (is) 2002-05-17
CR6678A (es) 2004-01-14
PT1110949E (pt) 2003-12-31
PL356662A1 (en) 2004-06-28
EP1110949A1 (en) 2001-06-27
TR200301841T4 (tr) 2004-01-21
TR200201643T2 (tr) 2002-11-21
ES2204458T3 (es) 2004-05-01
MA26852A1 (fr) 2004-12-20
JP2001181210A (ja) 2001-07-03
DE60005471T2 (de) 2004-04-22
KR100419681B1 (ko) 2004-02-21
IL140325A0 (en) 2002-02-10
HU0005001D0 (xx) 2001-02-28
CN1413190A (zh) 2003-04-23
EP1110949B1 (en) 2003-09-24
US6737437B2 (en) 2004-05-18
ATE250575T1 (de) 2003-10-15
AP2001002357A0 (en) 2001-12-31
SK8552002A3 (en) 2003-09-11
CO5251453A1 (es) 2003-02-28
US20010047105A1 (en) 2001-11-29
AU763983B2 (en) 2003-08-07
NO20022925L (no) 2002-06-18
EA005293B1 (ru) 2004-12-30
CA2329678A1 (en) 2001-06-22
NO20022925D0 (no) 2002-06-18
AP2002002555A0 (en) 2002-06-30
EE200200355A (et) 2003-10-15
CZ20022048A3 (cs) 2004-03-17
UA72293C2 (en) 2005-02-15
WO2001046140A1 (en) 2001-06-28
MXPA02006322A (es) 2002-12-13
US20020040149A1 (en) 2002-04-04
ZA200007694B (en) 2002-06-20
HUP0005001A3 (en) 2002-01-28
US6642266B2 (en) 2003-11-04
AU1293101A (en) 2001-07-03
OA12117A (en) 2006-05-04
PE20010953A1 (es) 2001-09-25
KR20010067415A (ko) 2001-07-12
DK1110949T3 (da) 2003-11-24
GEP20043203B (en) 2004-03-25
HUP0005001A2 (hu) 2001-12-28
EA200200505A1 (ru) 2002-12-26
AU7239300A (en) 2001-06-28

Similar Documents

Publication Publication Date Title
HRP20020537A2 (en) Ep4 receptor selective agonists in the treatment of osteoporosis
ES2291361T3 (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
US6376502B1 (en) Osteoporosis compounds
HRP980356A2 (en) Prostaglandin agonists
US20010056060A1 (en) Treatment of osteoporsis with EP2/EP4 receptor selective agonists
AU2008291814A1 (en) Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same
WO2009027803A2 (en) Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)- phenoxy)-acetic acid, free acid

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn